Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cue Biopharma (CUE) EBT Margin (2018 - 2025)

Cue Biopharma's EBT Margin history spans 8 years, with the latest figure at 244.28% for Q4 2025.

  • On a quarterly basis, EBT Margin fell 125419.0% to 244.28% in Q4 2025 year-over-year; TTM through Dec 2025 was 31.5%, a 4299.0% increase, with the full-year FY2025 number at 17.02%, up 5748.0% from a year prior.
  • EBT Margin hit 244.28% in Q4 2025 for Cue Biopharma, up from 343.09% in the prior quarter.
  • Over the last five years, EBT Margin for CUE hit a ceiling of 1498.48% in Q4 2024 and a floor of 50800.0% in Q2 2022.
  • Historically, EBT Margin has averaged 4582.56% across 5 years, with a median of 623.79% in 2021.
  • Biggest five-year swings in EBT Margin: plummeted -5042472bps in 2022 and later skyrocketed 4986274bps in 2023.
  • Tracing CUE's EBT Margin over 5 years: stood at 95.58% in 2021, then tumbled by -9763bps to 9426.49% in 2022, then surged by 92bps to 709.88% in 2023, then soared by 311bps to 1498.48% in 2024, then plummeted by -84bps to 244.28% in 2025.
  • Business Quant data shows EBT Margin for CUE at 244.28% in Q4 2025, 343.09% in Q3 2025, and 285.61% in Q2 2025.